Curex Review

FDA action on record

FDA reviewed getcurex.com and stated that claims concerning the compounded GLP-1 products offered there were false or misleading. Note this is Curex, not the separately named Curexa East LLC, which received an unrelated letter in 2023.

• Entity: Curex
• Action: FDA warning letter (MARCS-CMS 716821)
• Date: September 9, 2025

A warning letter is FDA's stated position that violations occurred. It is not a court finding, a recall, or a determination that any patient was harmed, and these letters concerned marketing claims about compounded GLP-1 products rather than a specific batch of medication. Companies often respond and correct the cited material. We publish this so you can weigh it yourself — read the letter and check the provider's current status before deciding.